How SS-31 (Elamipretide) Works: Cardiolipin Mechanism and the Heart Trials That Tested It

"Mitochondria-targeted" is the phrase that sells SS-31. It sounds precise, and in one respect it is: SS-31, the development name for elamipretide, has a well-characterized molecular target inside the cell. But a clear mechanism and a proven clinical outcome are two different things. What SS-31 does at the membrane level is one story; what happened when its cardiovascular trials put that mechanism to a human test is another. The second story is the clearest illustration of why the two belong in separate columns.

For a molecule-level overview first, see the SS-31 peptide guide. For the regulatory and longevity-claims angle, see SS-31 and Elamipretide: Barth Syndrome Approval vs Longevity Claims. This page is about the biology and the cardiac evidence specifically.

Evidence Snapshot

What SS-31 Is At The Molecular Level

SS-31, also called elamipretide, MTP-131, or Bendavia in older literature, is a small synthetic tetrapeptide. It was developed by Hazel Szeto and Peter Schiller, which is where the "SS" (Szeto-Schiller) naming comes from. Its structure alternates positively charged and aromatic amino acid residues, and that specific arrangement is what gives it an affinity for mitochondrial membranes.

Unlike most peptides, SS-31 can cross cell membranes and the outer mitochondrial membrane to reach the inner mitochondrial membrane, where it concentrates. That selective localization is the foundation of every downstream claim, which makes its binding target the place to start.

The Cardiolipin Target

SS-31's primary target is cardiolipin, an unusual phospholipid found almost exclusively on the inner mitochondrial membrane, where it makes up a substantial fraction of the membrane lipids. Cardiolipin is not just structural filler. It helps organize the protein complexes of the electron transport chain and shapes the folded membrane surfaces, called cristae, where energy production happens.

Mechanistic studies describe SS-31 as binding cardiolipin and altering the electrostatics of the membrane surface. Newer biophysical work in the Journal of Biological Chemistry frames part of its action as interacting with lipid bilayers and modulating surface charge, rather than acting purely as a simple antioxidant. The practical idea is that by associating with cardiolipin, SS-31 may help stabilize cristae architecture under stress.

This is the same evidence discipline behind How to Read a Peptide Study: a defined molecular target makes a research program reasonable, but it does not pre-decide the result of any clinical trial.

How Binding Could Protect Energy Production

The most cited mechanistic story involves cytochrome c, a small protein that normally shuttles electrons along the respiratory chain. When cytochrome c binds cardiolipin in certain conditions, it can switch to a peroxidase activity that damages the membrane and contributes to cell-death signaling. Laboratory work from the Szeto group reported that SS-31 modulates the cytochrome c/cardiolipin complex, limiting that harmful peroxidase behavior while preserving cytochrome c's useful electron-carrying role.

The proposed net effect is steadier oxidative phosphorylation, more efficient ATP synthesis, and less production of reactive oxygen species. Animal and isolated-tissue studies have extended this to cardiac ischemia-reperfusion models, where a cardiolipin-binding peptide reduced fragmentation of cristae networks after simulated heart injury.

It is a coherent hypothesis. Almost all of it sits at the level of cells, isolated mitochondria, and animal models. The question that matters is what happened when the mechanism reached people, and the cardiovascular trials answer it directly.

What The Cardiac Trials Showed

The heart was an obvious place to test a mitochondrial protectant, because reperfusion injury after a heart attack is partly driven by mitochondrial damage. The EMBRACE-STEMI study was a Phase 2a randomized, double-blind, placebo-controlled trial that gave intravenous elamipretide before reperfusion to first-time anterior STEMI patients undergoing primary percutaneous coronary intervention. The drug was safe and well tolerated, but it was not associated with a reduction in infarct size measured by creatine kinase-MB, the trial's primary efficacy measure.

Related work reported that elamipretide lowered circulating HtrA2, a mitochondrial stress marker, in STEMI patients. That is a biomarker signal consistent with the proposed mechanism, but a biomarker shift is not the same as a smaller infarct or better recovery. It is exactly the kind of result that supports continued study without proving clinical benefit.

Heart failure was the other major cardiac target. An early randomized study tested a single elamipretide infusion and cardiac function measures, and the later PROGRESS-HF Phase 2 trial evaluated left ventricular function in patients with heart failure with reduced ejection fraction. Across these cardiac programs, elamipretide did not establish itself as an effective heart-failure or reperfusion treatment. The company's later development pivoted toward rare mitochondrial disease, which is where the eventual approval came from.

Why Mechanism Did Not Equal Outcome

The cardiovascular story is a clean teaching case. SS-31 has a real, specific, repeatedly characterized mechanism. It localizes to mitochondria, binds cardiolipin, and changes mitochondrial behavior in the lab. And yet the human cardiac trials, which were directly designed around that mechanism, did not hit their primary endpoints. None of that means the biology is wrong. It means human physiology is complicated, timing and dosing matter, and a single molecular fix rarely controls a whole clinical outcome.

For readers evaluating online SS-31 claims, the lesson is concrete. When a source says "SS-31 protects mitochondria, so it boosts energy, recovery, and longevity," it is reasoning from mechanism to outcome and skipping the step where that reasoning was actually tested and often came up short. The same caution applies to other mitochondrial-themed peptides such as MOTS-c, where mechanism interest also runs ahead of durable clinical proof.

A useful habit is to ask which endpoint changed. A biomarker like HtrA2, an imaging measure of cardiac function, infarct size, walking distance, and survival are not interchangeable. A claim that drifts from a mechanism to a hard outcome without naming the trial that connects them is borrowing credibility it has not earned.

Safety And Regulatory Status

The cardiac trials reported that intravenous elamipretide was generally safe and well tolerated in monitored settings, but trial tolerability applies to specific study products, routes, and protocols. It does not validate unregulated research powders sold as SS-31, where identity, purity, sterility, and concentration are unverified.

On status, the only FDA-approved elamipretide product is Forzinity, granted accelerated approval in September 2025 for improving muscle strength in certain Barth syndrome patients. There is no approved cardiovascular, anti-aging, energy, or general wellness indication. The mechanism is investigational outside that narrow rare-disease use, and research-market SS-31 is a different product category from the approved drug.

For the broader framework, see Approved vs Investigational vs Compounded vs Research Peptides.

Reader Checklist

Before trusting a mechanism-based SS-31 claim, ask:

• Does the source separate the molecular target (cardiolipin binding) from a clinical outcome?
• Is the cited evidence from cells, isolated mitochondria, animals, or a human trial?
• If a human trial is cited, did it meet its primary endpoint, or only move a biomarker?
• Does it acknowledge that the cardiac trials did not establish efficacy?
• Does it distinguish trial-grade intravenous elamipretide from an online research vial?
• Does it state that the only approved use is a narrow Barth syndrome indication?
• Does it avoid using "mitochondria-targeted" as a stand-in for proven benefit?

SS-31 is one of the better-characterized mitochondrial peptides at the mechanism level, and its cardiolipin biology is well studied. But the most carefully designed human tests of that mechanism, in cardiovascular disease, did not deliver the outcomes the mechanism predicted. That gap is the most important thing to carry into any SS-31 claim.

References

• First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics, British Journal of Pharmacology / PubMed.
• Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis, British Journal of Pharmacology / PubMed.
• The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action, Journal of Biological Chemistry / PubMed.
• EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention, European Heart Journal.
• The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction, European Heart Journal: Acute Cardiovascular Care / PubMed.
• The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats, Communications Biology.
• Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide, Circulation: Heart Failure / PubMed.
• Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial, Journal of Cardiac Failure.
• Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential, International Journal of Molecular Sciences / PMC.
• FDA Grants Accelerated Approval to First Treatment for Barth Syndrome, U.S. Food and Drug Administration.

Disclaimer

This page is educational and is not medical advice. It does not provide dosing, injection, reconstitution, compounding, sourcing, purchasing, or treatment instructions for SS-31, elamipretide, or Forzinity. Decisions about heart disease, mitochondrial disease, or any prescription drug should be made with qualified healthcare professionals using the current product label and individual medical context.